Insider Buying: Profusa (NASDAQ:PFSA) Major Shareholder Buys $13,973.76 in Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt acquired 14,556 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $0.96 per share, with a total value of $13,973.76. Following the completion of the acquisition, the insider directly owned 108,301 shares of the company’s stock, valued at approximately $103,968.96. This represents a 15.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The shares were bought at an average price of $0.95 per share, for a total transaction of $1,299.60.
• On Wednesday, July 29th, Financial Lp Hrt bought 1,310 shares of Profusa stock. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $1,323.10.

Profusa Price Performance

PFSA opened at $0.96 on Friday. The business has a 50 day moving average price of $3.41 and a two-hundred day moving average price of $31.96. The company has a market capitalization of $182,932.00, a price-to-earnings ratio of -0.00 and a beta of 0.52. Profusa, Inc. has a 1-year low of $0.86 and a 1-year high of $1,297.50.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFSA. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.